Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929330 | 1.00 | CHRM5 (0.41) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL28917054 | 1.00 | CHRM5 (0.41) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL1524895 | 1.00 | CHRM5 (0.41) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| Ammonia Solution, Strong SCHEMBL9555998 | 0.96 | NOS1 (0.39) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL23070439 | 0.96 | CHRM5 (0.43) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL187659 | 0.96 | CHRM5 (0.43) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL11006113 | 0.96 | CHRM5 (0.43) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL2708909 | 0.96 | — | — | |
| SCHEMBL3224864 | 0.96 | CHRM5 (0.43) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL3222970 | 0.96 | CHRM5 (0.43) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5574037-A | MODULATED BY SINO-ATRIAL NODE, ANTIISCHEMIC AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-11-12 | — | — | US | claimed |
| EP-0431856-B1 | Heterocyclic compounds | ZENECA LTD (GB) | 1995-07-12 | — | — | EP | claimed |
| US-5332737-A | Cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-07-26 | — | — | US | claimed |
| EP-0431856-A2 | Heterocyclic compounds | ZENECA LIMITED (GB) | 1991-06-12 | — | — | EP | claimed |
| WO-2014128206-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128213-A1 | COMPOUNDS FOR USE IN INHIBITING HIV CAPSID ASSEMBLY | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2769723-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| EP-2769722-A1 | Compounds for use in inhibiting HIV capsid assembly | Ruprecht-Karls-Universität Heidelberg (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2011097607-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREEN FOR ANTI-VIRAL AGENT | SOUTHERN RESEARCH INSTITUTE (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | CHRM5 4242/4885CYP1A2 4452/4885ADRA2C 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.